
Investments
24Portfolio Exits
4Partners & Customers
10About Cedars-Sinai
Cedars-Sinai is a nonprofit academic healthcare organization that focuses on research, education, medical professionals, and the community. It offers programs and services for cancer, diabetes and endocrinology, digestive and liver diseases, ear, nose and throat, gynecology, heart, lung, neurology and neurosurgery, obstetrics, maternity, orthopedics, pain center, and primary care. The company was founded in 1902 and is based in Los Angeles, California.

Want to inform investors similar to Cedars-Sinai about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Cedars-Sinai News
Sep 13, 2023
The Smidt Heart Institute’s combined adult and pediatric program for extracorporeal membrane oxygenation, or ECMO, receives Gold Level Award for Excellence by the Extracorporeal Life Support Organization Professionals on the Smidt Heart Institute's ECMO Program team earned a prestigious designation recognizing their dedication to providing providing exceptional patient care. September 13, 2023 — The Smidt Heart Institute at Cedars-Sinai has earned a prestigious designation for its excellence in adult and pediatric extracorporeal membrane oxygenation, or ECMO --an often lifesaving treatment where blood is pumped outside of a patient’s body to a portable heart-lung machine, giving the patient’s own organs a rest. ECMO, once widely viewed by physicians as a last-chance therapy for patients close to death, was prominently employed with success during the COVID-19 pandemic, when the virus was at its peak and many patients arrived at the hospital on the edge of not surviving. Cedars-Sinai physicians learned that ECMO--in carefully selected patients--served as a bridge to lung transplantation, or at minimum, an opportunity for a patient’s body to heal their own lungs. Care teams also use ECMO in patients with heart disease to allow for recovery, or even as a bridge to heart transplantation. "This achievement is a testament to our dedication to providing exceptional care and promoting excellence in every aspect of our extracorporeal life support program," said Tyler Gunn, MD , director of the Extracorporeal Membrane Oxygenation Program in the Department of Cardiac Surgery. Richard Kim, MD , surgical director of the Guerin Family Congenital Heart Program and director of Pediatric and Congenital Cardiac Surgery, says the award not only signifies a commitment to providing exceptional adult and pediatric care but, "also assures the healthcare community of our adherence to high-quality standards, specialized equipment and supplies, well-defined patient protocols, and advanced education for all our staff members." Experts at the Smidt Heart Institute, a designated Center of Excellence, demonstrated superlative patient care by employing the highest-quality measures, evidence-based processes, and well-structured administrative systems. Other findings concluded employees demonstrated excellence in training, education, collaboration and communication, and the institute and medical center were found to foster a healing environment for families, patients and staff. "Being recognized as a Gold Level Center of Excellence showcases our leadership in extracorporeal life support and highlights our dedication to offering state-of-the-art healthcare services," said Joanna Chikwe, MD , chair of the Department of Cardiac Surgery at Cedars-Sinai and the Irina and George Schaeffer Distinguished Chair in Cardiac Surgery. "Our collective efforts and unwavering commitment to excellence, especially during the challenging times of the COVID-19 pandemic, have culminated in this incredible achievement." The institute’s success with ECMO led Smidt investigators to publish novel clinical data that supported wider use of ECMO. The data was published via an analysis in The New England Journal of Medicine, and included data from more than 3,000 lung transplantations that took place in the U.S. between Aug. 1, 2020, and Sept. 30, 2021. The data showed that during the pandemic, 7% of the nation’s lung transplants were performed to treat severe, irreversible lung damage caused by COVID-19. More than half of these patients needed either ventilators or ECMO before their transplant. The comprehensive team provided a cumulative total of more than 30,000 patient hours of ECMO support in 2022 alone. "We extend our heartfelt gratitude to each member of our multidisciplinary ECMO team, including nursing staff, perfusionists, pharmacists, program coordinators and administrators, intensivists, as well as medical and surgical staff," Gunn said. "This award serves as a reminder of our shared mission to save lives, improve patient outcomes, and continuously advance the field of medical and surgical care." For more information: www.cedars-sinai.org
Cedars-Sinai Investments
24 Investments
Cedars-Sinai has made 24 investments. Their latest investment was in K Health as part of their Series F on July 7, 2023.

Cedars-Sinai Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/17/2023 | Series F | K Health | $59M | Yes | Cedars-Sinai, and Undisclosed Investors | 1 |
1/11/2023 | Series B | Censinet | $9M | No | 18 | |
11/9/2022 | Series B | Fathom | $46M | Yes | 5 | |
10/12/2022 | Series B | |||||
3/28/2022 | Series C |
Date | 7/17/2023 | 1/11/2023 | 11/9/2022 | 10/12/2022 | 3/28/2022 |
---|---|---|---|---|---|
Round | Series F | Series B | Series B | Series B | Series C |
Company | K Health | Censinet | Fathom | ||
Amount | $59M | $9M | $46M | ||
New? | Yes | No | Yes | ||
Co-Investors | Cedars-Sinai, and Undisclosed Investors | ||||
Sources | 1 | 18 | 5 |
Cedars-Sinai Portfolio Exits
4 Portfolio Exits
Cedars-Sinai has 4 portfolio exits. Their latest portfolio exit was ClinicianNexus on June 08, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/8/2022 | Acquired | 1 | |||
Date | 6/8/2022 | |||
---|---|---|---|---|
Exit | Acquired | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 1 |
Cedars-Sinai Partners & Customers
10 Partners and customers
Cedars-Sinai has 10 strategic partners and customers. Cedars-Sinai recently partnered with Axiom Space on April 4, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/18/2023 | Partner | United States | Cedars-Sinai partners Axiom Space to grow stem cells in space Cedars-Sinai has partnered with Axiom Space to test the feasibility of producing stem cells in space-based laboratories , to aid the development of the next generation of cell therapies . | 1 | |
1/26/2023 | Partner | United States | Tia will partner with Cedars-Sinai to open additional clinics this year in Pasadena , Studio City and Culver City . | 8 | |
1/1/2022 | Partner | United States | 1 | ||
1/1/2022 | Partner | ||||
1/1/2022 | Partner |
Date | 4/18/2023 | 1/26/2023 | 1/1/2022 | 1/1/2022 | 1/1/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | Cedars-Sinai partners Axiom Space to grow stem cells in space Cedars-Sinai has partnered with Axiom Space to test the feasibility of producing stem cells in space-based laboratories , to aid the development of the next generation of cell therapies . | Tia will partner with Cedars-Sinai to open additional clinics this year in Pasadena , Studio City and Culver City . | |||
Sources | 1 | 8 | 1 |
Cedars-Sinai Team
8 Team Members
Cedars-Sinai has 8 team members, including current Chief Operating Officer, Executive Vice President, Jeffrey A. Smith.
Name | Work History | Title | Status |
---|---|---|---|
Jeffrey A. Smith | Chief Operating Officer, Executive Vice President | Current | |
Name | Jeffrey A. Smith | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Chief Operating Officer, Executive Vice President | ||||
Status | Current |